In order to better serve the beneficiaries, the Health Insurance Organisation wishes to inform the beneficiaries that the prescription criteria for the following pharmaceutical products have been extended:
[*]Xarelto [*]Eliquis [*]Pradaxa
As a result, a greater number of beneficiaries will be able to receive the above pharmaceutical products through the GHS.
Beneficiaries affected by this decision are requested to contact their treating physician to find out whether they meet the new criteria put in place by the Agency.
(MB/IC)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source
